Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Next-Generation Cancer Diagnostics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (Next-generation Sequencing, qPCR & Multiplexing, Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR), Protein Microarrays, DNA Microarrays)
5.2.2. By Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis)
5.2.3. By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others)
5.2.4. By Function (Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis)
5.2.5. By Region
5.2.6. By Company (2022)
5.3. Product Market Map
5.3.1. By Technology
5.3.2. By Application
5.3.3. By Cancer Type
5.3.4. By Function
5.3.5. By Region
6. North America Next-Generation Cancer Diagnostics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology (Next-generation Sequencing, qPCR & Multiplexing, Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR), Protein Microarrays, DNA Microarrays)
6.2.2. By Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis)
6.2.3. By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others)
6.2.4. By Function (Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis)
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Next-Generation Cancer Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Application
6.3.1.2.3. By Function
6.3.1.2.4. By Cancer Type
6.3.2. Canada Next-Generation Cancer Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Application
6.3.2.2.3. By Function
6.3.2.2.4. By Cancer Type
6.3.3. Mexico Next-Generation Cancer Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Application
6.3.3.2.3. By Function
6.3.3.2.4. By Cancer Type
7. Europe Next-Generation Cancer Diagnostics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology (Next-generation Sequencing, qPCR & Multiplexing, Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR), Protein Microarrays, DNA Microarrays)
7.2.2. By Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis)
7.2.3. By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others)
7.2.4. By Function (Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis)
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Next-Generation Cancer Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Application
7.3.1.2.3. By Cancer Type
7.3.1.2.4. By Function
7.3.2. United Kingdom Next-Generation Cancer Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Application
7.3.2.2.3. By Cancer Type
7.3.2.2.4. By Function
7.3.3. France Next-Generation Cancer Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Application
7.3.3.2.3. By Cancer Type
7.3.3.2.4. By Function
7.3.4. Italy Next-Generation Cancer Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Application
7.3.4.2.3. By Cancer Type
7.3.4.2.4. By Function
7.3.5. Spain Next-Generation Cancer Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Application
7.3.5.2.3. By Cancer Type
7.3.5.2.4. By Function
8. Asia-Pacific Next-Generation Cancer Diagnostics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology (Next-generation Sequencing, qPCR & Multiplexing, Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR), Protein Microarrays, DNA Microarrays)
8.2.2. By Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis)
8.2.3. By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others)
8.2.4. By Function (Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis)
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Next-Generation Cancer Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Application
8.3.1.2.3. By Cancer Type
8.3.1.2.4. By Function
8.3.2. Japan Next-Generation Cancer Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Application
8.3.2.2.3. By Cancer Type
8.3.2.2.4. By Function
8.3.3. India Next-Generation Cancer Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Application
8.3.3.2.3. By Cancer Type
8.3.3.2.4. By Function
8.3.4. Australia Next-Generation Cancer Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Application
8.3.4.2.3. By Cancer Type
8.3.4.2.4. By Function
8.3.5. South Korea Next-Generation Cancer Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Application
8.3.5.2.3. By Cancer Type
8.3.5.2.4. By Function
9. South America Next-Generation Cancer Diagnostics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology (Next-generation Sequencing, qPCR & Multiplexing, Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR), Protein Microarrays, DNA Microarrays)
9.2.2. By Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis)
9.2.3. By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others)
9.2.4. By Function (Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis)
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Next-Generation Cancer Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Application
9.3.1.2.3. By Cancer Type
9.3.1.2.4. By Function
9.3.2. Argentina Next-Generation Cancer Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Application
9.3.2.2.3. By Cancer Type
9.3.2.2.4. By Function
9.3.3. Colombia Next-Generation Cancer Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Application
9.3.3.2.3. By Cancer Type
9.3.3.2.4. By Function
10. Middle East and Africa Next-Generation Cancer Diagnostics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology (Next-generation Sequencing, qPCR & Multiplexing, Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR), Protein Microarrays, DNA Microarrays)
10.2.2. By Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis)
10.2.3. By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others)
10.2.4. By Function (Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis)
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Next-Generation Cancer Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Application
10.3.1.2.3. By Cancer Type
10.3.1.2.4. By Function
10.3.2. Saudi Arabia Next-Generation Cancer Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Application
10.3.2.2.3. By Cancer Type
10.3.2.2.4. By Function
10.3.3. UAE Next-Generation Cancer Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Application
10.3.3.2.3. By Cancer Type
10.3.3.2.4. By Function
10.3.4. Kuwait Next-Generation Cancer Diagnostics Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Technology
10.3.4.2.2. By Application
10.3.4.2.3. By Cancer Type
10.3.4.2.4. By Function
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. Competitive Landscape
14.1. Business Overview
14.2. Product Offerings
14.3. Recent Developments
14.4. Financials (As Reported)
14.5. Key Personnel
14.6. SWOT Analysis
14.6.1. Janssen Pharmaceuticals Inc
14.6.2. Novartis AG
14.6.3. F Hoffmann-La Roche AG
14.6.4. Koninklijke Philips NV
14.6.5. Abbott Laboratories Inc
14.6.6. GE Healthcare Inc
14.6.7. Thermo Fisher Scientific Inc
14.6.8. Agilent Technologies Inc
14.6.9. Illumina Inc
14.6.10. QIAGEN NV
15. Strategic Recommendations
16. About Us & Disclaimer